Drugs / AZD5634
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02950805 | May 2017 → Apr 2018 | respiratory system disorder | AstraZeneca | Completed | Missed primary |
| Phase 1 | NCT02679729 | Feb → Oct 2016 | cystic fibrosis | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5634 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02679729 ↗ |
| Action | Inhibit | “AZD5634 inhibited ENaC in the nasal epithelium” PMID 35227647 ↗ Feb 2022 |
| Route | Inhaled | “administered by jet nebulizer” NCT02679729 ↗ |